This is a summary of the European public assessment report (EPAR) for Xaluprine. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Xaluprine.
Therapeutic Indication
### Therapeutic indication Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.
Therapeutic Area (MeSH)
ATC Code
L01BB02
ATC Item
mercaptopurine
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| 6-mercaptopurine monohydrate | N/A | 6-mercaptopurine monohydrate |
EMA Name
Xaluprine (previously Mercaptopurine Nova Laboratories)
Medicine Name
Xaluprine (previously Mercaptopurine Nova Laboratories)
Aliases
N/ANo risk management plan link.
